Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d01f6469c1b1fbf6a49910d7d068ec4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43595 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1767 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 |
filingDate |
2012-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79ec74e48a2d3bf995f88f536541866e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_779ae3230c87c129fa78d4c1ec8062ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18269b2953527a4530e67204cf3d4183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ef9ab750df5c4c135950fe0325be0ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1775413e69e443406ee59569e7ccd3dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18a437110d07043c803b025068fd5e00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_caf354f4766e0e7fb2c3b8dcefb9fa1c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d697106d59bba5042ac5026258487e27 |
publicationDate |
2013-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2013052507-A1 |
titleOfInvention |
TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS |
abstract |
Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016146583-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016146575-A1 |
priorityDate |
2011-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |